Shopping Cart
Remove All
Your shopping cart is currently empty
Visilizumab
(Synonyms: HuM291, Anti-Human CD3E Recombinant Antibody) Copy Product Info
🥰Excellent
Synonyms: HuM291, Anti-Human CD3E Recombinant Antibody
Catalog No. T76839 Copy Product Info
🥰Excellent
Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease.
Visilizumab
Cas No. 219716-33-3
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,330 | - | In Stock | |
| 25 mg | $1,980 | - | In Stock | |
| 50 mg | $2,680 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.6% (SDS-PAGE); 99.4% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease. |
| In vitro | Methods: Visilizumab (1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10,000 ng/mL, 2-48 hours (samples were taken and analyzed at 2, 4, 20, 24, and 48 hours)) was used to treat lamina propria T cells and observe their cell growth. Results: Visilizumab was able to induce dose- and time-dependent apoptosis of lamina propria T cells. [1] |
| Synonyms | HuM291, Anti-Human CD3E Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD3 |
| Molecular Weight | 144.64 kDa |
| Cas No. | 219716-33-3 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Visilizumab in vitro | Visilizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.